Quantcast
Home > Quotes > ACHV

Achieve Life Sciences, Inc. Common Shares (ACHV) Quote & Summary Data

ACHV 
$1.75
*  
0.09
4.89%
Get ACHV Alerts
*Delayed - data as of Nov. 14, 2018  -  Find a broker to begin trading ACHV now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ACHV Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
12
Today's High / Low
$ 1.90 / $ 1.70
Share Volume
135,011
50 Day Avg. Daily Volume
1,387,284
Previous Close
$ 1.84
52 Week High / Low
$ 32 / $ 1.80
Market Cap
11,761,930
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.52

Intraday Chart

Shares Traded

Share Volume:
135,011
50 Day Avg. Daily Volume:
1,387,284

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -8.13

Trading Range

The current last sale of $1.75 is -2.78% Lower than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.90 $ 32
 Low: $ 1.70 $ 1.80

Company Description (as filed with the SEC)

We are a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation. Our focus is to address the global smoking health epidemic, which is a leading cause of preventable death and is responsible for approximately six million deaths annually worldwide. Cytisine is an established 25-day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by Sopharma AD for over 20 years under the brand name TabexTM. It is estimated that over 20 million people have used cytisine to help treat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase 3 clinical trials in Europe and New Zealand. Both trials were published in the New England Journal of Medicine in September 2011 and December 2014, respectively. Cytisine is a naturally occurring, plant-based alkaloid from the seeds of the Laburnum anagyroides plant.  ... More ...  


Risk Grade

Where does ACHV fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.85
Open Date:
Nov. 14, 2018
Close Price:
$ 1.75
Close Date:
Nov. 14, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x